An innovative polymeric platform consisting polyglycerol and polyoxazoline engineered for advanced wound healing and targeted gene therapy. This innovative copolymer system rapidly regenerates damaged tissue while serving as an efficient therapeutic delivery vehicle.

Innovation Explanation

Our patented technology leverages a unique copolymer design that combines polyglycerol or poly(vinyl alcohol) with polyoxazoline and other biomolecules in the chain ends. The system self-assembles into supramolecular aggregates with precisely tunable sizes, ensuring deep tissue penetration and optimized therapeutic delivery. Preclinical studies have confirmed its rapid wound-closure capability and excellent biocompatibility in both diabetic and non-diabetic models. In addition to wound healing, the platform is ideally suited for delivering nucleic acids, opening doors to gene therapy applications. The straightforward, scalable synthesis process supports low-cost, high-volume manufacturing while addressing urgent clinical needs in regenerative medicine.

Key Innovation Features and Advantages

• Rapid healing capability: Promote fast wound-closure in acute and chronic diabetic wounds
• Tunable structure and aggregate formation: The tunable structure and self-assembles into aggregates with customizable sizes, facilitating tissue interaction and targeted delivery.
• Superior biocompatibility: Extensive in vitro and in vivo tests validate minimal toxicity and high cell compatibility, ensuring safe therapeutic application.
• Modular versatility: Designed to function both as a wound-healing agent and a carrier for nucleic acid delivery, enabling multifunctional therapeutic strategies.
• Scalable manufacturing: The robust and cost-effective synthesis process allows for industrial-scale production with consistent quality.

Use cases

• Chronic and diabetic wound healing: Accelerates the closure of non-healing wounds and diabetic ulcers, significantly reducing recovery time and complications.
• Gene and nucleic acid delivery: Acts as an efficient and safe carrier for DNA/RNA therapeutics, ideal for regenerative medicine and precision treatment applications.
• Topical therapeutic applications: Can be formulated into gels or coatings for sustained release of drugs at wound sites, enhancing local treatment effectiveness.

Commercial opportunities

• Expanding healthcare markets: Addresses the multi-billion-dollar market for chronic wound care and diabetic ulcer management with a solution that reduces overall treatment costs.
• Cutting-edge biotech applications: Offers a promising platform for partnering with pharmaceutical and gene therapy companies to bring next-generation treatments to market.
• Investment in scalable innovation: Simplified production and proven preclinical success position the technology for rapid commercialization and attractive ROI in regenerative medicine.

Current Status

The technology is at an advanced preclinical stage with comprehensive in vitro and in vivo validations demonstrating safety and efficacy. Ongoing activities include fine-tuning for clinical trials and preparing for regulatory submissions, with plans for early-phase human studies paving the way to market entry.